IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A REVIEW ON: CORONAVIRUS OUTBREAKS

Prem Lata[1], Kirti Kaushal[2], Shalini Vashisht[3], Jyoti Gupta[4]

1. Prem Lata, Student of Bachelors of Pharmacy, IEC University, Baddi

2. Kirti Kaushal, Assistant Professor, School of Pharmacy, IEC University, Baddi

3. Shalini Vashisht, Assistant Professor, School of Pharmacy, IEC University, Baddi

4. Jyoti Gupta, Associate Professor, Head of Department, IEC University, Baddi

Abstract

The sudden pandemic among several communicable diseases is having an extremely damaging effect mostly on lives of hundreds of thousands of individuals. These conditions have put a lot of pressure on our medical system and other basic public services, but they have also put pressure on the economy, researchers, and governments as they work to find responses to the economic crisis, develop vaccines, and maintain community expectations, appropriately. The most common infections that really can damage anyone, no matter their gender or age, are acute respiratory tract infections (ARTIs). Before the biggest Chinese celebration at the end of the year, a variety of dangerous diseases attacked. Our capacity to fight the threat of highly contagious viruses, mainly coronaviruses, which are known to be highly dangerous to human beings,has been challenged by one of the most current ARTI (acute respiratory tract infection) using such, COVID-19. Even though the coronavirus has already been identified disease since 1960s. SARS-CoV-2 is actually a part of the Coronaviridae family, which is a subdivision of the Nidovirales order. Although such a pharmaceutical cannot currently successfully treat COVID-19, broad-spectrum antivirals and other medications are showing some promise in treating SARS-CoV-2 infections. More than 15 different medications were employed in order to investigate actual identification of COVID-19 infections.Like bevacizumab, fluvoxamine, lopinavir, ritonavir, tocilizumab, and sarilumab. Patients having COVID-19 have just a wide range of challenges due to the absence of effective medicine to deal with the problem. As the population is growing, medications will be essential in the hopes of maintaining and minimizing the financial damage imposed on by the disease. Common human coronaviruses, such as subtypes 229E, NL63, OC43, and HKU1, were also generally responsible for the prevalent cold as well as other mild to moderate upper respiratory tract symptoms. Usually people contract this virus at some period within their lifetimes. Normally, these symptoms last for two weeks. Human coronaviruses were generally spread because of an

infected person sneezing and coughing towards people who inhaled in the air. Avoid travelling, Wash your hands properly and apply sanitizer,During cough and sneezing use mask.

Keywords: Coronavirus, Pandemic, Communicable disease, Vaccine.

Introduction

Millions of people's lives having recently very seriously impacted by that of outbreak with different infectious diseases [1,2] and public essential services, additionally they have caused a stress on economics, researchers, and politicians as their try to solve the hard times, discover vaccines, and dealing with public expectations, respectively. [3-6]. At the end the calendar year, just before the biggest Chinese celebration, a variety of dangerous diseases attacked [7]. In Wuhan, one of the greatest cities in China, many chronic pneumonia cases with similar symptoms emerged, attracting the public's attention [8,9]. Finally, applying genome sequencing technology, the sickness's cause was established to be a model coronavirus called as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease was named the designation coronavirus disease 2019, or COVID-19[10]. That after the Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV (which stands for severe acute respiratory syndrome coronavirus) arrived, (severe acute respiratory syndrome) SARS-CoV-2 is another coronavirus with only a strong ability to infect humans [11,12]. Overall number virus 48,539,872 infected cases and 1,232,791 confirmed deaths are due to COVID-19 have been identified in 215 different countries and territories internationally as of 5 November 2020 [13]. The pharmaceutical industry has already been affected by this infection, which now has established an important international major health issue [14].

Outbreaks of Respiratory Viruses in History

Acute respiratory tract infections (ARTIs) are the most common infections which can harm anybody, no matter their gender or age [15]. Common pathogen, Hemophilus influenzae, Moraxella catarrhalis, Infectious diseases A or B ("the flu"), acute viral virus (RSV), parainfluenza, adenoviruses, coronaviruses, and other microorganisms are commonly to responsible for any of these diseases [16,17]. Until now, in terms of infectiousness and medical problem, one of most serious infections are commonly linked to coronaviruses, influenza A or B, and RSV, all of which have been responsible for several epidemics and pandemics [18]. Both corona and pandemic infections undoubtedly produce more serious problems than many others, too. Besides that, these viruses, which have damaged a significant population, but especially elderly people, have been connected to some of the most serious and prolonged both past and present disease outbreaks [19]. The term "Pandemic" is derived from the Greek and means "affecting everyone" people" [20]. It almost always represents the widespread of an infection throughout that or maybe more regions of the world, as contrasted to the local spread of illnesses, which become called as epidemics and therefore are major contributing factors by different seasons influenza viruses. Outbreaks commonly happen when emerging disease subtypes spread the

disease and spread from one person to another when persons have such a meaningful immunity that is strong to fight such infections. Pandemics were caused by different genetic mechanisms, involve unpredictable patterns of deaths between many people of all ages, and vary considerably in their emergence and repeat periods.

First Epidemics and Coronaviruses

The ARTI (acute respiratory tract infection) pandemic, COVID-19, has once again called attention to the deadly viruses and challenged our capacity for fighting the threat of highly contagious viruses, including coronaviruses, which are known to really be harmful to human beings, to the test [21]. The capability of the coronavirus to spread dangerous epidemics really suddenly was discovered, considering that this virus has been known to infect people since the 1960s. The third important respiratory disease outbreak connected to the coronavirus in the last twenty years has significantly damage economical system. SARS-CoV-2 is really a belonging to the family Coronaviridae, which makes it a constituent of something like the Nidovirales order [22]. Coronavirinae and Torovirinae are really the two subfamilies that belong the whole family. Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus are also the four genera which make it up entire coronavirinae subfamily. The lineages A, B, C, and D of something like the genus Betacoronavirus have been before identified. Embecovirus (lineage A), Sarbecovirus (lineage B), Merbecovirus (lineage C), and Nobecovirus have now been classified as subgenera of the Betacoronavirus (lineage D). The subgenus Sarbecovirus of something like the genus Betacoronavirus contains SARS-CoV-2. Coronaviruses are round, contained viruses with such a diameter have between 80 and 120 nm. Sometimes, they could be pleiomorphic. Club-shaped spike projections arising from the virus' surface provide it and its different look [23]. The coronavirus takes its name from all these spikes, helping provide them their unique design which like a solar corona. Coronaviruses were heat- and Ultraviolet light, so they can be maintained at a temperature of 80 C for a long time. But, most viruses can be made harmless by heating these at 56 degrees Celsius for thirty minutes, as this is usually performed by scientists. Coronaviruses may also be declared ineffective by peracetic acid, 75% ethanol, and disinfectants which contain chlorine [24].

Medication and Vaccination of COVID-19

Drugs: Although COVID-19 cannot already successfully treatable with such a drug, broad-spectrum antivirals and other drugs have demonstrated some potential in treating SARS-CoV-2 infections. The diagnosis of COVID-19 infections has been investigated utilizing approximately 15 different medications. These include tocilizumab and sarilumab, bevacizumab, fluvoxamine, lopinavir, and ritonavir. Those who have included umifenovir, nitazoxanide, ivermectin, and chloroquine and hydroxychloroquine [25]. The benefit of so many antiviral drugs, especially ribavirin and remdesivir, in treating the condition had been investigated. For examples, remdesivir (GS-5734) has been demonstrated to be successful against MERS and SARS in animal experiments and has a broad spectrum of activity [26,27,28]. Remdesivir was very well known for blocking RNA-dependent RNA

polymerase activity, that inhibits viral RNA from just being produced. Remdesivir was also investigated in some of these trials to treat COVID-19, but there were a few undesirable effects [29,30,31]. Ribavirin is a generally used medication used to prevent which is known to inhibit the manufacture of ribonucleoprotein. It also inhibits early viral gene transcription, which would be known to prevent the virus that growing and spreading [32]. Ribavirin trials are all still pending just because a few studies have suggested that the drug has very little benefit on COVID-19 patients [33]. The US FDA actually declared clearly that this drug is unsuccessful for the prevention of virus. Similar to something like this, other antiviral medicines including lopinavir and ritonavir, which also are known to be successful treat MERS and (severe acute respiratory syndrome) SARSCoV-1 patients, are also being investigated to treat COVID-19 patients [34]. According to multiple experiments, the virus can't match in vitro whenever chloroquine and its derivatives were also administered [35]. Some of the possible mechanisms of action includes increasing endosomal pH, which will enable viral proteins to disintegrate, and dealing with the terminal glycosylation of the cell's receptor ACE2 to prevent viral binding [36]. Angiotensin-converting enzyme 2, which contains binding sites for (severe acute respiratory syndrome) SARS-CoV S proteins, is identified as being impacted by the drug [37]. But still, recently released research about the multinational experiments performed do not suggest any positive effects associated with the medication [38,39]. The acute respiratory distress syndrome is the biggest problem with COVID-19 infections (ARDS). Corticosteroids can be used to prevent the cytokine storm and thereby reduce the risk of developing ARDS. Even so, their antitumor effect also placed individuals at greater risk for problems including secondary infections [40].

Management of Coronavirus

COVID-19 patients experience a number of challenges due to the absence of effective medicine to treat the condition. In hopes of surviving and minimize the financial damage carried about by the disease, growing population medications will be necessary. People include treatments such extracorporeal membrane oxygenation and artificial liver systems (ALS) (ECMO). Countless experiments and other studies show indicated that there is no specific, successful treatment for COVID-19; therefore, patients are controlled through a variety of medicine combinations [41]. The vaccine manufactured by the University of Oxford/AstraZeneca represents one of more than a dozen in clinical phase 3 trials, according to the WHO, that were developed by many organizations and research groups [42]. Unfortunately, the trials were ultimately stopped because a number of the patients were suffering side effects. The vaccines manufactured by CanSino Biological Inc./Beijing Institute of Biotechnology, Sinovac, Moderna/NIAID (National Instititute of Allergy & Infectious Diseases), many more are between those currently experiencing clinical phase 3 experiments [43]. Those who are mostly inactivated or non-replicating viral transmitters [44]. The Pfizer-BioNTech COVID-19 vaccine had only been finally approved and suggested. Extra added medicines include the Sinovac, COVID-19 vaccine by Moderna, and Sputnik V.

Symptoms of Corona Virus

The common cold as well as other mild to moderate upper respiratory tract disorders were generally brought over by common human coronaviruses, such as subtypes 229E, NL63, OC43, & HKU1. The majority of human beings receive such virus at some stage in their lives. These symptoms commonly only continue a short duration.

Possible symptoms are

1. A congested nose
2. Throat pain and swelling
3. Fever
4. Headache

A human feel uncomfortable Human coronaviruses can cause temporary infections of the respiratory tract inside the lower respiratory system, such as bronchitis and pneumonia. Infants, especially among the elderly, people with weaker immune systems, and people who have cardiopulmonary disease are much more at risk for this. MERSCoV and (severe acute respiratory syndrome) SARS-CoV, two other human coronaviruses, are known to frequently cause serious conditions. Fever, coughing, as well as breathing difficulties all major MERS symptoms which commonly lead to pneumonia. Every third or fourth patient with MERS that has been diagnosed must have died suddenly. Cases from MERS continue to be discovered, mainly in the Arab World. Temperature, shivering, as well as muscle pain all common SARS symptoms which also generally progressed to asthma. Since 2004, there haven't been any human (severe acute respiratory syndrome) SARS reported cases anywhere in the universe.

How Coronavirus Affects the Human Life

Human coronaviruses were mostly generally transferred through sneezing and coughing from such an infected person towards people who breathe in the air. close skin contact, such as shaking hands or hugging touching the mouth, nose, as well as eyes while getting in to the contact with an infected surface or object before even sanitizing your hands. Usually, faecal matter infection People commonly infect universal human coronaviruses all through the autumn and winter seasons in the United States.

How can coronavirus get protected?

1. Avoid travelling.
2. Maintain distance from other persons.
3. During coughing and sneezing, use mask and mouth with something like a tissue before discarding that tissue in the trashcan.
4. Wash your hands regularly and use of santizer.
5. Floors and objects must be clean properly & sanitized.

Conclusion:

During Covid 19, Millions of people's lives having recently very seriously impacted by that of outbreak with different infectious diseases not only have these conditions imposed pressure on our medical services and public essential services, additionally they have caused a stress on economics, researchers, and politicians as their try to solve the hard times, discover vaccines, and dealing with public expectations, respectively.

In Wuhan, one of the greatest cities in China, many chronic pneumonia cases with similar symptoms emerged, attracting the public's attention. Acute respiratory tract infections (ARTIs) are the most common infections which can harm anybody, no matter their gender or age. . The lineages A, B, C, and D of something like the genus Betacoronavirus have been before identified. Embecovirus (lineage A), Sarbecovirus (lineage B), Merbecovirus (lineage C), and Nobecovirus have now been classified as subgenera of the Betacoronavirus (lineage D). Coronaviruses shape round, contained viruses with such a diameter have between 80 and 120 nm. Sometimes, they could be pleiomorphic. Club-shaped spike projections arising from the virus' surface provide it and its different look. COVID-19 patients experience a number of challenges due to the absence of effective medicine to treat the condition. In hopes of surviving and minimize the financial damage carried about by the disease, growing population medications will be necessary. The majority of human beings receive such virus at some stage in their lives. These symptoms commonly only continue a short duration. a congested nose, throat pain and swelling fever headache, close skin contact, such as shaking hands or touching the mouth, nose, as well as eyes while getting in to the contact with an infected surface or object before even sanitizing your hands.

REFERENCE

1. Liao, Y.; Xu, B.; Wang, J.; Liu, X. A new method for assessing the risk of infectious disease outbreak. Sci. Rep. 2017, 7, 40084.

2. Grubaugh, N.D.; Ladner, J.T.; Lemey, P.; Pybus, O.G.; Rambaut, A.; Holmes, E.C.; Andersen, K.G. Tracking virus outbreaks in the twenty-first century. Nat. Microbiol. 2019, 4, 10–19.

3. Goenka, A.; Liu, L. Infectious diseases, human capital and economic growth. Econ. Theory 2019, 70, 1–47.

4. Hua, J.; Shaw, R. Corona virus (Covid-19) “infodemic” and emerging issues through a data lens: The case of china. Int. J. Environ. Res. Public Health 2020, 17, 2309.

5. McCloskey, B.; Heymann, D.L. SARS to novel coronavirus—Old lessons and new lessons. Epidemiol. Infect. 2020, 148, e22.

6. Nkengasong, J. China’s response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response. Nat. Med. 2020, 26, 310–311.

7. Wang, C.; Horby, P.W.; Hayden, F.G.; Gao, G.F. A novel coronavirus outbreak of global health concern. Lancet 2020, 395, 470–473.

8. Zhou, M.; Zhang, X.; Qu, J. Coronavirus disease 2019 (COVID-19): A clinical update. Front. Med. 2020.

9. Jiang, S.; Xia, S.; Ying, T.; Lu, L. A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. Cell. Mol. Immunol. 2020, 17, 554–554.

10. Yang, P.; Wang, X. COVID-19: A new challenge for human beings. Cell. Mol. Immunol. 2020, 17, 555–557.

11. Van Der Hoek, L.; Pyrc, K.; Jebbink, M.F.; Vermeulen-Oost, W.; Berkhout, R.J.; Wolthers, K.C.; Wertheim-van Dillen, P.M.; Kaandorp, J.; Spaargaren, J.; Berkhout, B. Identification of a new human coronavirus. Nat. Med. 2004, 10, 368–373.

12. Cui, J.; Li, F.; Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019, 17, 181–192.

13. World Health Organization. Novel Coronavirus (2019 -nCoV): Situation Report, 3. 2020. Available online: https://apps.who.int/ iris/bitstream/handle/10665/330762/nCoVsitrep23Jan2020-eng.pdf (accessed on 23 December 2020).

14. Lupia, T.; Scabini, S.; Pinna, S.M.; Di Perri, G.; De Rosa, F.G.; Corcione, S. 2019-novel coronavirus outbreak: A new challenge. J. Glob. Antimicrob. Resist. 2020, 21, 22–27.

15.Castagnoli, R.; Votto, M.; Licari, A.; Brambilla, I.; Bruno, R.; Perlini, S.; Rovida, F.; Baldanti, F.; Marseglia, G.L. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: A systematic review. JAMA Pediatrics 2020, 174, 882–889.

16.Gröndahl, B.; Puppe, W.; Hoppe, A.; Kühne, I.; Weigl, J.A.; Schmitt, H.-J. Rapid identification of nine microorganisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: Feasibility study. J. Clin. Microbiol. 1999, 37, 1–7.

17. Bitko, V.; Musiyenko, A.; Shulyayeva, O.; Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 2005, 11, 50–55.

18. Brundage, J.F. Interactions between influenza and bacterial respiratory pathogens: Implications for pandemic preparedness. Lancet Infect. Dis. 2006, 6, 303–312.

19. Bedford, J.; Enria, D.; Giesecke, J.; Heymann, D.L.; Ihekweazu, C.; Kobinger, G.; Lane, H.C.; Memish, Z.; Oh, M.-D.; Schuchat, A. COVID-19: Towards controlling of a pandemic. Lancet 2020, 395, 1015–1018.

20. Morens, D.M.; Folkers, G.K.; Fauci, A.S. What Is a Pandemic; The University of Chicago Press: Chicago, IL, USA, 2009

21. Docea, A.O.; Tsatsakis, A.; Albulescu, D.; Cristea, O.; Zlatian, O.; Vinceti, M.; Moschos, S.A.; Tsoukalas, D.; Goumenou, M.; Drakoulis, N. A new threat from an old enemy: Re-emergence of coronavirus. Int. J. Mol. Med. 2020, 45, 1631–1643.

22. King, A.M.; Lefkowitz, E.; Adams, M.J.; Carstens, E.B. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses; Elsevier: Amsterdam, The Netherlands, 2011; Volume 9.

23. Fehr, A.R.; Perlman, S. Coronaviruses: An overview of their replication and pathogenesis. In Coronaviruses; Springer: Berlin/Heidelberg, Germany, 2015; pp. 1–23.

24. Yang, P.; Wang, X. COVID-19: A new challenge for human beings. Cell. Mol. Immunol. 2020, 17, 555–557.

25. Shaffer, L. 15 drugs being tested to treat COVID-19 and how they would work. Nat. Med. 2020.

26. Li, G.; De Clercq, E. Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV); Nature Publishing Group: Berlin, Germany, 2020.

27. Sheahan, T.P.; Sims, A.C.; Graham, R.L.; Menachery, V.D.; Gralinski, L.E.; Case, J.B.; Leist, S.R.; Pyrc, K.; Feng, J.Y.; Trantcheva, I. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 2017, 9, 396.

28. Agostini, M.L.; Andres, E.L.; Sims, A.C.; Graham, R.L.; Sheahan, T.P.; Lu, X.; Smith, E.C.; Case, J.B.; Feng, J.Y.; Jordan, R. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018, 9, e00221-18.

29. Omrani, A.S.; Saad, M.M.; Baig, K.; Bahloul, A.; Abdul-Matin, M.; Alaidaroos, A.Y.; Almakhlafi, G.A.; Albarrak, M.M.; Memish, Z.A.; Albarrak, A.M. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: A retrospective cohort study. Lancet Infect. Dis. 2014, 14, 1090–1095.

30. Khalili, J.S.; Zhu, H.; Mak, N.S.A.; Yan, Y.; Zhu, Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J. Med. Virol. 2020

31. Yao, T.T.; Qian, J.D.; Zhu, W.Y.; Wang, Y.; Wang, G.Q. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease-19 treatment option. J. Med. Virol. 2020, 92, 556–563.

32. Biot, C.; Daher, W.; Chavain, N.; Fandeur, T.; Khalife, J.; Dive, D.; De Clercq, E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J. Med. Chem. 2006, 49, 2845–2849.

33. Vincent, M.J.; Bergeron, E.; Benjannet, S.; Erickson, B.R.; Rollin, P.E.; Ksiazek, T.G.; Seidah, N.G.; Nichol, S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2005, 2, 1–10.

34. Savarino, A.; Boelaert, J.R.; Cassone, A.; Majori, G.; Cauda, R. Effects of chloroquine on viral infections: An old drug against today's diseases. Lancet Infect. Dis. 2003, 3, 722–727.

35. Geleris, J.; Sun, Y.; Platt, J.; Zucker, J.; Baldwin, M.; Hripcsak, G.; Labella, A.; Manson, D.K.; Kubin, C.; Barr, R.G. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med. 2020.

36. Boulware, D.R.; Pullen, M.F.; Bangdiwala, A.S.; Pastick, K.A.; Lofgren, S.M.; Okafor, E.C.; Skipper, C.P.; Nascene, A.A.; Nicol, M.R.; Abassi, M. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N. Engl. J. Med. 2020.

37. Zha, L.; Li, S.; Pan, L.; Tefsen, B.; Li, Y.; French, N.; Chen, L.; Yang, G.; Villanueva, E.V. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med. J. Aust. 2020, 212, 416–420.

38. Viner, R.M.; Russell, S.J.; Croker, H.; Packer, J.; Ward, J.; Stansfield, C.; Mytton, O.; Bonell, C.; Booy, R. School closure and management practices during coronavirus outbreaks including COVID-19: A rapid systematic review. Lancet Child Adolesc. Health 2020, 4, 397–404.

39. Cohen, J. The Race Is on for Antibodies That Stop the New Coronavirus; American Association for the Advancement of Science: Washington, DC, USA, 2020

40. Pang, J.; Wang, M.X.; Ang, I.Y.H.; Tan, S.H.X.; Lewis, R.F.; Chen, J.I.-P.; Gutierrez, R.A.; Gwee, S.X.W.; Chua, P.E.Y.; Yang, Q. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): A systematic review. J. Clin. Med. 2020, 9, 623.

41. Lurie, N.; Saville, M.; Hatchett, R.; Halton, J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. 2020, 382, 1969–1973.